Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: A randomized controlled trial

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 8, 2009, Pages 919-926

  Ortonne, J P ^a   Ganslandt, C ^b   Tan, J ^c   Nordin, P ^d   Kragballe, K ^e   Segaert, S ^f  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b LEO PHARMA A S   (Denmark)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Dermatology Clinic   (Sweden)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Calcipotriol plus betamethasone dipropionate scalp formulation; Quality of life; Scalp psoriasis

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CORTICOSTEROID; DITHRANOL; RETINOID; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; XAMIOL;

ADULT; AGED; ARTICLE; BELGIUM; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCALP PSORIASIS; SHORT FORM 36; SINGLE BLIND PROCEDURE; SKINDEX 16; SOCIAL PSYCHOLOGY; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; CHEMISTRY, PHARMACEUTICAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; PSYCHOLOGY; QUALITY OF LIFE; SCALP DERMATOSES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651160702     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03221.x     Document Type: Article

References (37)

1. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992 49 : 396 400.
2. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005 64 (Suppl. 2 ii18 ii23.
3. Schafer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006 212 : 327 337.
4. Van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001 2 : 159 165.
5. Dawber R, van Neste D. Hair and Scalp Disorders. Common Presenting Signs, Differential Diagnosis and Treatment. JB Lippincott : Philadelphia, 1995.
6. National Psoriasis Foundation Benchmark Survey. Available at: http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf (Last accessed: September 2007).
7. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001 50 : 11 15.
8. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol 1993 32 : 188 190.
9. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006 54 : 420 426.
10. Van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998 197 : 326 334.
11. van der Vleuten CJ, Van de Kerkhof PC. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs 2001 61 : 1593 1598.
12. Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994 189 : 260 264.
13. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3396 patients. Dermatology 2001 203 : 153 156.
14. Kragballe K, Austad J, Barnes L et al. Efficacy results of a 52-week randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris. Dermatology 2006 213 : 319 326. (Pubitemid 44837020)
15. Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006 20 : 39 44.
16. ®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006 154 : 1155 1160. (Pubitemid 43727399)
17. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003 4 : 221 224.
18. Richards HL, Fortune DG, O'Sullivan TM, Main CM, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999 41 : 581 583.
19. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008 217 : 107 113.
20. Jemec GBE, Ganslandt C, Ortonne JP et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized double-blind, controlled trial. J Am Acad Dermatol 2008 59 : 455 463.
21. Van de Kerkhof PCM, Hoffmann V, Anstey A et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind controlled trial. Br J Dermatol 2008 E-pub ahead of print : Nov 25 2008. DOI. 2008.08927.
22. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis. Br J Dermatol 2008 Accepted for publication.
23. Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004 9 : 131 135.
24. Wolkenstein P. Living with psoriasis. J Eur Acad Dermatol Venereol 2006 20 : 28 32.
25. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-36® Health Survey. Qualitymetric Incorporated, Lincoln, Rhode Island, 2000.
26. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin disease. J Cutan Med Surg 2001 5 : 105 110.
27. Brazier JE, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 292.
28. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 407.
29. de Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002 138 : 1221 1227.
30. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la BM. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007 21 : 1151 1160.
31. Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002 82 : 131 135.
32. Guenther L, Van de Kerkhof PC, Snellman E et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002 147 : 316 323.
33. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004 151 : 663 668.
34. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004 140 : 408 414.
35. Krueger GG, Langley RG, Finlay AY et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005 153 : 1192 1199.
36. Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006 154 : 1161 1168.
37. Revicki D, Willian MK, Saurat JH et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 158 : 549 557.